Find trials
Search tips

Objectivity In Allocation Of Advanced Heart Failure (SOCIALHF) Therapies Trial

Overview

About this study

The purpose of this study is to assess the real-world effectiveness and implementation process for allocation of advanced therapies for heart failure (HF), heart transplants and ventricular assist devices, in randomized controlled trial in which participants will be randomized at the group level.

Allocation of advanced therapies for HF is subjective and often biased. We have developed a multi-component standardized protocol (SOCIAL HF) that is designed to achieve racial/ethnic and gender equity in the allocation process by using evidence-based tools to reduce bias, improve objectivity, and improve group function.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria - Centers:

  • Active United Network for Organ Sharing heart transplant and ventricular assist device center.
  • Centers that routinely evaluate at least 50 minoritized racial/ethnic patients and 50 women for advanced heart failure therapies (heart transplant and ventricular assist devices) over 2 years.

Inclusion Criteria - Individual Participants:

  • Advanced therapy professionals from the selected centers (i.e., coordinators, physicians, pharmacists, nurses, social workers) that would be included on allocation attendance sheets submitted to United Network for Organ Sharing.
  • Participants for the interview portion will be a subset of otherwise eligible advanced therapy professionals who are included on selection meeting attendance sheets at an included center.

Exclusion Criteria - Centers:

  • Centers unable to fully participate in the training and evaluation measures.
  • If the center ceases to be an active heart failure/transplant center.

Eligibility last updated 7/13/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Shannon Dunlay, M.D., M.S.

Contact us for the latest status

Contact information:

Shannon Dunlay

5072665591

dunlay.shannon@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20598522

Mayo Clinic Footer